Pancreatic Ductal Adenocarcinoma: New Insights into the Actions of Vitamin A

Eduardo Mere Del Aguila  Xiao-Han Tang  Lorraine J. Gudas
Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA

Keywords
Pancreas · Pancreatic cancer · Pancreatic stellate cells · Retinoic acid receptors

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) is a gland-forming malignancy arising in the pancreas. It is estimated that in developed countries the incidence of PDAC will continue to rise, and PDAC is now the fourth leading cause of cancer-related deaths in the USA. The mortality of PDAC patients closely parallels the incidence rate, as this malignancy generally remains asymptomatic until it reaches an advanced stage. Summary: The poor prognosis results from the aggressive nature of the tumor, late detection, and resistance to chemotherapy and radiotherapy. Retinoids, vitamin A (retinol) and its metabolites, such as retinoic acid (RA), play critical roles in important biological functions, including cell growth and differentiation, development, metabolism, and immunity. The actions of retinoids in maintaining normal pancreatic functions have generated considerable research interest from investigators interested in understanding and treating PDAC. Altered expression of retinoid receptors and other RA signaling pathway genes in human cancers offers opportunities for target discovery, drug design, and personalized medicine for distinct molecular retinoid subtypes. Key Messages: The goals of this review are to explore the potential activities of retinoids in the pancreas, to assess the evidence that retinoid functions become dysregulated in PDAC, and to describe the actions of retinoids in new therapies developed to increase patient survival.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy. It is the fourth leading cause of cancer-related death in the USA [1]. Unfortunately, due to its late presentation, only 15–20% of patients are candidates for surgical intervention. PDAC is predicted to become the second leading cause of cancer death within a decade if progress in treatment continues to be only incremental [2]. PDAC is characterized by rapid progression, an extremely poor prognosis, and limited treatment options [3].

Among the factors that increase the risk of this malignancy are obesity, cigarette smoking, and increased consumption of animal fat [4]. A greater risk for PDAC development is also associated with pancreatitis, type 2 diabetes [5, 6], and Helicobacter pylori infection [7]. Disruptions/mutations in various genes (TP53, SMAD4, ARID1A, ROBO2, KDM6A, PREX2) increase the incidence of PDAC [8].

K-RAS mutations occur very frequently in pancreatic cancer [9]. K-RAS activity is an important and early event in tumorigenesis [10, 11]. Various studies show that an activating mutation in K-RAS occurs in from 47 to 100% of PDAC cases, most commonly at codon 12 [12–14].

FOLFIRINOX (the combination of folinic acid, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin), a cancer therapy, is reported to have a survival advantage compared to gemcitabine (a DNA synthesis inhibitor) alone for PDAC treatment [15]. Nab-paclitaxel (an antimicrotubular agent), a combination therapy with albumin-based nab-paclitaxel and gemcitabine, is associated with
significant improvement in median overall survival (OS) and progression-free survival compared to gemcitabine alone [16].

Retinoids are defined as a group of micronutrients that include vitamin A (retinol) and its metabolites. All-trans retinoic acid (RA) is the biologically active form of vitamin A because RA acts as an agonist for the RA receptors (RAR-α, RAR-β, and RAR-γ) to regulate gene expression [17]. Various retinoids are used as chemotherapeutic agents in oncology [18]. Retinoids are effective components of some current cancer therapies because they can act both by promoting stem cell differentiation and changing the pattern of gene expression in tumor cells to make them more sensitive to other therapies [19]. Recently, a clinical trial of RA in pancreatic cancer has started [20]. Because of this clinical interest in retinoids for PDAC treatment and epidemiological studies demonstrating an inverse relationship between dietary vitamin A consumption and PDAC development [21], here we explore the actions of retinoids in the normal pancreas and in PDAC.

**General Overview of the Actions of Retinoids**

Retinoids are naturally occurring, low-molecular-weight, fat-soluble, unsaturated isoprenoids that play essential roles in various aspects of mammalian physiology, including spermatogenesis, fertilization, pregnancy maintenance, morphogenesis, organogenesis, and fetal and perinatal growth. Retinaldehyde plays a key role in vision, and RA in gene regulation. Nutritional deficiency in vitamin A is still a major public health concern in the developing world, causing blindness and death [22].

RA inhibits cell proliferation and induces cell differentiation in many malignant tissues [18]. RA exerts its pleiotropic effects on cellular growth and differentiation through acting as a ligand for the RA receptors (RAs). The transcriptional regulatory activity of RA is mediated by 6 distinct ligand-dependent transcription factors, 3 RARs (RAR-α, RAR-β, and RAR-γ), and 3 retinoid X receptors (RXR-α, RXR-β, and RXR-γ). The RAs and RXRs are members of the steroid/thyroid/retinoid superfamily of nuclear hormone receptors and recognize specific response elements present within genes to then regulate transcription and subsequent epigenetic changes [23]. Most retinoid actions within the body involve transcriptional regulatory effects that are mediated primarily by RA [17]. Thus, RA is a potent transcriptional regulator that directly controls expression of more than 500 genes, and these RA target genes vary in different cell types [24]. The three different RARs regulate unique and different target genes [24].

RA has a well-studied, essential role in patterning in the development of numerous organs, including the hindbrain, spinal cord, heart, eyes, forelimbs, buds, lungs, genital urinary tract, and pancreas [25]. Deficient or excessive retinoid signaling, arising either through dietary retinoid insufficiency or through alterations in genes involved in retinoid metabolism or signaling, can give rise to a wide spectrum of embryonic defects, emphasizing the importance of the regulation of intracellular metabolites of all-trans retinol (ROH) and the proper levels of RA for assuring normal embryonic development [26]. The synthesis and degradation of RA are complex processes, however, involving many specific proteins and enzymes (Fig. 1). Retinoids (retinyl esters, retinol, and provitamin A carotenoids, such as β-carotene) must be obtained from the diet [27].

**Retinoids in the Pancreas: Glucose Regulation**

Retinol (ROH) is required for the maintenance of both pancreatic β-cell mass and for glucose-stimulated insulin secretion in adult mice [28, 29]. Reintroduction of retinoids into the diet of retinoid-deficient mice restored pancreatic retinoid levels, glycemic control, normal islet size distribution, normal β-cell to α-cell ratios, endocrine hormone profiles, and RARβ2 and RARY2 transcript levels [29]. It is also clear that retinoids are needed to maintain β-cell mass within islets and to prevent β-cell apoptosis [29].

In adult rodents, an isomer of all-trans RA, 9-cis-RA, rapidly attenuates glucose sensing and insulin secretion, and pancreatic 9-cis-RA levels vary inversely with serum insulin levels [30]. Importantly, both RA and ROH levels are reduced in human PDAC tissue compared to healthy tissue, and the levels of these retinoids are similarly reduced in pancreata obtained from a mouse PDAC model [31]. Patients are often hyperglycemic for a mean period of 36–30 months before PDAC diagnosis [32], which is associated with the fact that both RA and ROH levels are reduced in human PDAC tissue.

**Retinoid Actions in Pancreatic Development**

The pancreas is composed of endocrine and exocrine compartments which are responsible for maintaining body glucose homeostasis and digesting food, respectively [33]. The endocrine pancreas is defined by islet cells which secrete hormones, such as insulin and glucagon, to regulate the blood glucose level. The RA-signaling pathway plays critical roles in a wide range of developmental processes at multiple stages during embryogenesis [34]. In the pancreas, RA signaling is necessary for the onset of pancreogenesis; previous studies have demonstrated that inhibition of this RA signaling pathway leads to pancreas agenesis [35].
High levels of RA are crucial for initial pancreas specification, and RA is used in several protocols for stem cell differentiation and for pancreatic endoderm specification in culture. This use of RA is also supported by gene expression analyses in mice demonstrating the presence of many key RA pathway genes in the embryonic pancreas [36]. Exocrine cell differentiation is also controlled in part by retinoid signaling during development [37].

The disruption of RA signaling in all pancreatic progenitors led to the formation of a smaller pancreas that contained fewer β (Insulin), α (Glucagon), and δ (Somatostatin) cells at embryonic day e16.5 and e18.5 [38]. Disrupting RA signaling using the tamoxifen-inducible Pdx1:creEsr1 allele at e9.5, a slightly later stage of development after the pancreatic progenitor population has been established, also resulted in the formation of a smaller pancreas and a significant reduction in islet cluster formation and fewer hormone producing cells [39]. Recent results further establish the importance of RA signaling in the endocrine progenitor population for appropriate mouse and human β-cell specification [40].

Retinoid Actions in Pancreatic Acinar Cells

The exocrine pancreas consists of acinar cells which synthesize digestive enzymes such as amylase, and ductal cells responsible for transport of digestive enzymes to the duodenum for digestion. Acinar cells are enzyme-secreting cells that release amylase, lipases, and proteases; some differentiated acinar cell identity proteins include Ptf1a, MIST1, GATA6, NR5A2, and PAF1 [41]. Debate exists regarding whether acinar cell carcinoma of the pancreas is unique from PDAC [42, 43]. However, acinar cell carcinoma of the pancreas responds to treatment differently and rates of OS (overall survival) are not similar [44].

PDACs form pancreatic duct-like structures under the microscope and are therefore called “pancreatic ductal adenocarcinomas (PDACs),” which are among the deadliest malignancies in humans [1]. There is some evidence that PDAC may originate from pancreatic ductal cells through the development of pancreatic intraepithelial neoplasias after the first activating gene mutation in KRAS [45]. In addition to pancreatic ductal cells, pancreatic acinar cells (PAC) contribute to the development of
PDAC through acinar-to-ductal metaplasia (ADM) [46]. In ADM, PAC can dedifferentiate to an embryonic progenitor phenotype that expresses ductal markers [41]. The concept that acinar cell plasticity plays an important role in PDAC tumorigenesis has received increasing attention more recently [47, 48]. When acinar cells receive inflammatory signals during pancreatic injury, such as pancreatitis, ADM can occur. Research with mouse models suggests that in PDAC the cell of origin is the mature acinar cell, and pancreatitis-induced ADM has been proposed as a potential mechanism of PDAC initiation in mice [47]. Indeed, pancreatitis is the top risk factor for PDAC in humans [49, 50]. However, how pancreatitis accelerates PDAC development is not well understood.

Multiple factors have been implicated in mediating ADM, such as K-RAS hyperactivity and increased inflammatory signaling [51–53]; in the presence of internal or external stress signaling of oncogenic K-RAS, inflammatory cytokines, or growth factors that activate epidermal growth factor receptor, acinar cells can spontaneously transdifferentiate into duct-like structures [47, 54]. For instance, Sox9 is not normally expressed in acinar cells [55], but in the presence of hyperactive K-RAS, higher expression of Sox9 in ductal and centroacinar cells is induced during ADM, and Sox9 is expressed at high levels in pancreatic intraepithelial neoplasias [56–58].

RA is an important signaling molecule in the development of the embryonic pancreas and plays a major role in the differentiation of endocrine and ductal cells, predominantly through paracrine actions and upregulation of PDX-1 during development [59]. In the K-rasLSL.G12D/+; Pdx1-Cre (KC) transgenic murine model of PDAC researchers demonstrated that inhibition of 15-hydroxyprostaglandin dehydrogenase increased Cyp26a1 levels (Fig. 1), resulting in a reduction in RA in the pancreas and an enhancement of K-RAS-driven PDAC progression. Furthermore, pharmacological doses of RA suppressed 15-hydroxyprostaglandin dehydrogenase inhibition-induced tumor progression in these KC mice [60].

In the normal pancreas, significant RA signaling in the adult is reported to be restricted to the islets and a small number of exocrine (acinar and centro-acinar) cells, as shown by an RA responsive element being activated in a murine model (RARE-LacZ) [61]. However, when these same RARE-LacZ mice are treated with cerulein, which can induce cell damage and subsequent pancreatitis, loss of acinar cell mass, pancreatic fibrosis, and ADM, they show increased retinoid signaling, as assessed by LacZ, in a large percentage of acinar cells immediately after the cerulein treatment is stopped [61]. These data suggest that RA signaling is activated to repair and regenerate the acinar cell population following injury. This could involve dedifferentiation of acinar cells to a more stem-like state or differentiation of stem cells in the pancreas [62].

Retinoid Actions in Pancreatic Stellate Cells

Pancreatic stellate cells (PSCs) are fibroblastic cells that represent 4–7% of all pancreatic cells. PSCs also play an essential role in the regeneration of the pancreas after partial pancreatectomy. In the liver, about 50%–80% of vitamin A in the body is stored in hepatic stellate cells as retinyl esters [63, 64]. Normal PSCs are quiescent and store retinol in cytoplasmic, lipid vesicles; however, during PDAC progression they lose vitamin A and acquire an activated, myofibroblast-like, contractile phenotype [65]. Proliferation of acinar and islet cells increases when co-cultured with activated PSCs, suggesting that PSC activation could promote PDAC progression [66]. Retinoids are involved in preventing or slowing PSC activation and disease progression [67]. In humans, PSCs express all three RA receptors (RARs), albeit at different levels, and treatment with RA mechanically reprograms PSCs to promote quiescence in vitro and inhibit pancreatic cancer cell invasion [31, 68].

In chronic disease, the repeated activation of PSCs causes pancreatic fibrosis, characterized by disruption of the normal cytoarchitecture and excessive deposition of extracellular matrix, particularly fibrillar collagens, proteoglycans, and fibronectin [64]. In the tumor environment, TGF-β can be released from cancer cells, infiltrating immune cells, or atypical acinar cells [64]. Importantly, PSC activation by TGF-β can initiate an autocrine, positive feedback loop which perpetuates an activated PSC phenotype [65]. PDAC is characterized by a strong desmoplastic reaction or stromal fibrosis which is driven by PSCs and may create a microenvironment that regulates tumor growth, metastasis, and chemoresistance [69]. This desmoplastic reaction has been the focus of several studies that have concentrated on the complex nature of the stromal components and their contributions to disease progression [70–72]. All of these observations about the behavior of PSCs are important because activated PSCs promote growth of PDAC [73], and the excessive extracellular matrix (called desmoplasmia, desmoplastic reaction, or stromal reaction to a tumor) also increases the resistance of pancreatic cancers to chemotherapy and radiation. PSCs additionally indirectly stimulate tumor growth and metastasis by promoting angiogenesis [65, 74].

RA has the ability to reduce the activation of stellate cells in both liver and pancreas [75]. Human PDAC samples show greatly reduced RA signaling and levels of retinoid receptors [31]. For this reason, targeting PSC activation can be considered as a useful therapeutic strategy in PDAC, and understanding the roles played by retinoids in the modulation of the quiescent/activated state of PSCs is certainly of importance [31, 76]. PSCs reduce their proliferation and synthesis of extracellular matrix and
α-smooth muscle actin when they are treated with RA or vitamin A [77, 78]. RA promotes the quiescent, nonactivated state of PSCs [67], and elimination of activated PSCs can also occur via apoptosis [79]. RA also restores mechanical quiescence in PSCs through a mechanism involving RA receptor beta (RARβ)-dependent reduction in actomyosin contractility [80]. RA treatment reduces the ability of PSCs to generate high traction forces and to adapt to extracellular mechanical cues; suppression of force-mediated extracellular matrix remodeling inhibits local cancer cell invasion in three-dimensional organotypic models [80].

Patients with PDAC demonstrated significantly lower levels of vitamin A, as measured previously in other studies [81, 82]. An inverse correlation between serum pentraxin 3, a protein associated with local inflammation, and VA levels was found in this study, and RA treatment reduces the PTX3 protein level [81].

Effects of RA with Other Therapies for Pancreatic Cancer

RA possesses antitumor activity in part through its ability to induce cellular differentiation. Even though retinoids show promising preclinical activity in human solid tumors, they have not yet been translated into effective systemic treatments for PDAC. We think that recognizing how retinoids function in pancreatic tumor cells could provide insights into how to design more successful approaches and strategies for retinoid therapies.

One major effect of RA is an increase in RAR levels in different cells, especially an increase in RARβ [83]. Decreased expression of RARβ has been suggested to play a key role in the maintenance of the malignant phenotype in human PDAC [84]. In animal studies, stimulation of RARα by retinoids resulted in a time- and dose-dependent inhibition of PDAC cell growth [85]. RA also restores the quiescent state of PSCs, which are part of the desmoplastic stroma surrounding cancer cells, acting as a barrier for chemotherapeutic drugs and thus generally promoting tumor growth and resistance [95, 96].

In PDAC cell lines, RA plus gemcitabine synergistically reduced proliferation in part by decreasing expression of p21 activated kinases [93], and by inhibiting K-RAS activation [97]. Interestingly, in a phase I trial conducted in patients with diverse solid tumors the HDAC inhibitor MS-275 (Entinostat), in combination with 13-cis-RA, prolonged stable disease (6 months) in a patient with unresectable, chemotherapy-resistant pancreatic cancer, thus suggesting some effectiveness of this combination in controlling disease progression [98]. Repurposing RA as a stromal-targeting agent with gemcitabine-nab-paclitaxel is likely safe and tolerable. This combination will be evaluated in a phase II randomized controlled trial for locally advanced PDAC [20].

The clinical application of RA is, however, hampered by its hydrophobicity, poor bioavailability, and instability; thus, some researchers have used a nanoparticulate system for drug delivery purposes [99]. 13-cis RA and 1,25-Vi
dicatin D3 blocked cell invasion and induced the expression of TIMP-3 through an inactivation of JNK pathways [90–94]. Moreover, RA can target PSCs, which are part of the desmoplastic stroma surrounding cancer cells, acting as a barrier for chemotherapeutic drugs and thus generally promoting tumor growth and resistance [95, 96].

The Know Your Tumour trial is the first specifically in PDAC to demonstrate longer survival in patients who received matched therapies relative to those with actionable mutations who received mismatched therapies and those who bore no such alterations, with a median OS of 1 year or longer [101]. Various studies have also been conducted to evaluate the chemopreventive potential of retinoids as single agents and in combination drug regimens with other chemotherapeutic agents [102, 103].

Conclusions

Important questions regarding the potential roles of retinoids in preventing pancreatic cancer development need to be answered. For instance, it is necessary to establish which genes that play critical roles in pancreas development are induced or regulated by retinoids and also act in PDAC prevention/treatment. Personalized cancer care is anchored on the premise that a patient’s cancer can be molecularly characterized in real time, informing prog-
nosis and predicting therapeutic responses. For that reason, it will be necessary to obtain a more precise understanding of the activation of genes involved in retinoid metabolism and of how the levels of retinoids may influence the survival of patients with PDAC. Future therapeutic approaches will benefit from RNA sequencing of tumors to determine the status of RA signaling genes when administering RA-based treatments to oncology patients [102].

Future research could also provide important information by identifying which retinoids are active against tumor cells that carry specific mutations. Furthermore, continued research on RA signaling mechanisms and the dysregulation of RA signaling in cancer should provide valuable insights into how new retinoid-targeted therapies might be designed for PDAC patients.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2021 Jan;67(1):7–30.
2. Ryan DP, Hong TS, Bardees N. Pancreatic adenocarcinoma. N Engl J Med. 2014 Sep;371(11):2140–1.
3. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Fries H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010 Apr;7(4):e1000267.
4. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCaill RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018 Nov;24(43):4846–61.
5. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer: a Meta-analysis of Cohort Studies. Eur J Cancer. 2011 Sep;47(13):1928–37.
6. Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control. 2011 Feb;22(2):189–97.
7. Trasino SE, Benoit YD, Gudas LJ. Vitamin A receptors, and cancer. Annu Rev Pathol. 2011;6:345–64.
8. Duffy MJ, Sturgeon C, Lamerz R, Bazhin AV. Reduced retinoids and retinoid receptors’ expression in pancreatic cancer. J Cell Physiol. 2011 Feb;226(2):322–30.
9. Gudas LJ, Wagner JA. Retinoids regulate stem cell differentiation. J Cell Physiol. 2011 Feb;226(2):322–30.
10. Vyas KS. A global clinical view on vitamin A and retinooids. Am J Clin Nutr. 2012 Nov;96(5):1204S–6S.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

NIH ROI CA205258 to L.J.G., Cancer Pharmacology Training Grant T32 CA062948 to E.M.D.A., and Weill Cornell Funds.

Author Contributions

E.M.D.A. wrote the paper, and X.-H.T. and L.-J.G. edited and revised the paper. All authors read and approved the final manuscript.
Retinoids and Pancreatic Cancer

Sharma A, Smyrk TC, Levy MJ, Topazian MA, Chari ST. Fasting blood glucose levels provide estimate of duration and progression of pancreatic cancer before diagnosis. Gastroenterology. 2018;155(2):490–e2.

Wong CH, Li YJ, Chen YC. Therapeutic potential of targeting acinar cell reprogramming in pancreatic cancer. World J Gastroenterol. 2016 Aug;22(31):7046–57.

Glyshelnic KB, Duester G. Retinoic acid signaling pathways. Development. 2007;134(13):2163–76.

Kobayashi H, Spilde TL, Bhatia AM, Buckingham NP, Niedergethmann M, Saeger HD, et al. Retinoic acid signaling controls mouse pancreatic development through epithelial-mesenchymal interactions. Gastroenterology. 2002 Oct;124(3):1331–40.

Ostrom M, Loffler KA, Edfalk S, Selander L, Dahl U, Ricordi C, et al. Retinoic acid promotes the generation of pancreatic endocrine progenitor cells and their further differentiation into beta-cells. PLoS One. 2008 Jul 30;3(7):e2841.

Gu D, Dubauskaitė J, Melton DA. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development. 2002 May;129(10):2447–57.

Lorberbaum DS, Kishore S, Rosselot C, Sarraf G, Dubauskaite J, Melton DA. Direct evidence of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia. Oncogene. 2013 Apr;32(15):1950–8.

Kopp IL, Gromepe M, Sander M. Stem cells versus plasticity in liver and pancreas regeneration. Nat Cell Biol. 2016 Mar;18(3):238–45.

Gukovskiy I, Li N, Todoric J, Gukovskaya A, Karin M. Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatic and pancreatic cancer. Gastroenterology. 2013 Jun;144(6):1199–e4.

Becker AE, Hernandez YG, Frucht H, Lucas AL. Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol. 2014 Aug;20(32):11182–98.

Hezel AF, Gurumurthy S, Granot Z, Swisa A, Chu GC, Bayless G, et al. Pancreatic LBKI deletion leads to acinar polarity defects and cystic neoplasms. Mol Cell Biol. 2008 Apr;28(7):2414–25.

Liou GY, Djöppler H, Necela B, Krishna M, Crawford D, Hembree MJ, et al. Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs. J Cell Biol. 2013 Aug;202(3):563–77.

Liou GY, Djöppler H, DeGiornio KE, Zhang L, Leitges M, Crawford HC, et al. Mutant KRas-induced mitochondrial oxidative stress in acinar cells upregulates EGFR signaling to drive formation of pancreatic precancerous lesions. Cell Rep. 2016 Mar;14(10):2325–36.

Liou GY, Djöppler H, Braun UB, Panajiotou R, Scotti Buzhardt M, Radisky DC, et al. Protein kinase D1 drives pancreatic acinar cell reprogramming and progression to intrapapillary neoplasia. Nat Commun. 2015 Feb;6:2620.

Seymour PA, Freude KK, Tran MN, Mayes EE, Jensen J, Kist R, et al. SOX9 is required for maintenance of the pancreatic progenitor cell pool. Proc Natl Acad Sci U S A. 2007 Feb;104(6):1865–70.

Morris JP, Cano DA, Sekine S, Wang SC, Hebrok M. Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J Clin Invest. 2010 Feb;120(2):508–20.

Kopp L, van, Figura G, Mayes E, Liu FF, Du- bois CL, Morris JP, et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell. 2012 Dec;22(6):737–50.

Prévot PP, Simon A, Grémont A, Colletti M, Khalalhie A, Van den Steen G, et al. Role of the ductal transcription factors HNF6 and Sox9 in pancreatic acinar-to-ductal metaplasia. Gut. 2012 Dec;61(12):1723–32.

Tulachan SS, Dei R, Kawaihara Y, Tsuji S, Nakajima S, Masui N, et al. All-trans retinoic acid induces differentiation of ducts and endocrine cells by mesenchymal/epithelial interactions in embryonic pancreas. Diabetes. 2003 Jan;52(1):76–84.

Arima K, Ohmuroya M, Miyake K, Koiva M, Uchihara F, Iwaya D, et al. Inhibition of 13-PGDH causes Kras-driven tumor expansion through prostaglandin E2-ALDH1 signaling in the pancreas. Oncogene. 2019 02;38(8):1211–24.

Colvin EK, Susanto JM, Kench JG, Ong VN, Mawson A, Pines M, et al. Retinoid signaling in pancreatic cancer, injury and regeneration. PLoS One. 2011;6(12):e29075.

Lytle NK, Ferguson LP, Rajbandhari N, Gilroy K, Fox RG, Deshpande A, et al. A multiscale map of the stem cell state in pancreatic adenocarcinoma. Cell. 2019 Apr;177(3):572–86.e22.

Apte MV, Pirola RC, Wilson JS. Pancreatic stellate cells: a starring role in normal and diseased pancreas. Front Physiol. 2012;3:344.

McCarroll JA, Naim S, Shanbhag G, Russia N, Lee J, Kavallaris M, et al. Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Front Physiol. 2014;5:141.

Apte MV, Wilson JS. Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells. J Gastroenterol. 2012 Mar;27(Suppl 2):69–74.

Otta S, Nishimura M, Murakami Y, Birukawa NK, Yoneda A, Nishita H, et al. Involvement of pancreatic stellate cells in regeneration of remnant pancreas after partial pancreatectomy. PLoS One. 2016;11(12):e0165747.

Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, et al. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression. Gastroenterology. 2011 Oct;141(4):967–971.e1–4.

Brun P, Wongsiroj N, Blaner WS. Retinoids in the pancreas. Hepatobiliary Surg Nutr. 2016 Feb;5(1):1–14.

Vonlaufen A, Joshi S, Qu C, Phillips PA, Xu Z, Parker NR, et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 2008 Apr;68(7):2085–93.

Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014 Jun;25(6):735–47.

Wilson JS, Pirola RC, Apte MV. Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression. Front Physiol. 2014;5:52.

Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, et al. Genotype-pancreatic ductal adenocarcinoma tissue tension to induce matricular fibrosis and tumor progression. Nat Med. 2016 May;22(5):497–505.

Dunik S, Lopatto Lindman J, Ansari D, Gundewar C, Andersson R. Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. Pancreatology. 2010;10(6):673–81.

Haqq J, Howells LM, Garcea G, Metcalfe MS, Steward WP, Dennison AR. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies. Eur J Cancer. 2014 Oct;50(15):2570–82.

Friedman SL. Hepatic stellate cells: protein, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008 Jan;88(1):125–72.

Carmona R, Barrena S, Muñoz-Chápuli R. Retinoids in stellate cells: development, repair, and regeneration. J Dev Biol. 2019 May;7(2).

Oncol Res Treat 2022;45:291–298
DOI: 10.1159/000522425
80 Chronopoulos A, Robinson B, Sarper M, Cornevs E, Auernheimer V, Lachowski D, et al. ATRA mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion. Nat Commun. 2016 Sep; 7: 12630.

81 Goulart MR, Watt J, Siddiqui I, Lawlor RT, Imrali A, Hughes C, et al. Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. Mol Pharm. 2013 Mar 04; 10(3): 408–14.

82 Huang X, Gao Y, Zhi X, Inoue K, Ohtsuka H, Ohtsuki S, et al. All-trans retinoic acid enhances gemicitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase. Eur J Pharm Sci. 2017 May 30; 103: 116–21.

83 Yao J, Zhang L, Zhou J, Liu H, Zhang Q. Efficiency and inhibition of cancer stem cells. Biomater. 2016 Aug 28;33(3): G819–26.

84 Polvani S, Tarocchi M, Tempesti S, Galli A, Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, et al. Phase I Study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer. 2012 Jan;106(1): 77–84.

85 Rhim AD, Stanger BZ. Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways. Prog Mol Biol Transl Sci. 2010;97: 41–78.

86 Sun R, Liu Y, Li SY, Shen S, Du XJ, Xu CF, et al. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials. 2015 Jan;37: 405–14.

87 Herreros-Villanueva M, Er TK, Bujanda L. Retinoic acid reduces stem cell-like features in pancreatic cancer cells. Pancreas. 2015 Aug; 44(6): 918–24.

88 Davis-Yadley AH, Malafa MP. Vitamins in pancreatic cancer: a review of underlying mechanisms and future applications. Adv Nutr. 2015 Nov;6(6): 774–802.

89 Kuroda H, Tachikawa M, Uchida Y, Inoue K, Ohtsuka H, Ohtsuki S, et al. All-trans retinoic acid enhances gemicitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase. Eur J Pharm Sci. 2017 May 30; 103: 116–21.

90 Yao J, Zhang L, Zhou J, Liu H, Zhang Q. Efficiency and inhibition of cancer stem cells. Biomater. 2016 Aug 28;33(3): G819–26.

91 Thomas D, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 2019 01 21;18(1):14.

92 Pettersson F, Colston KW, Dalgleish AG. Retinoic acid enhances gemicitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase. Eur J Pharm Sci. 2017 May 30; 103: 116–21.

93 Cristiano MC, Cosco D, Celia C, Tudose A, Mare R, Paolino D, et al. Anticancer activity of all-trans retinoic acid-loaded liposomes on human thyroid carcinoma cells. Colloids Surf B Biointerfaces. 2017 Feb 01;150: 408–16.

94 Cheng YH, Chiang EI, Syu JN, Chao CY, Lin HY, Lin CC, et al. Treatment of 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 inhibits TNF-alpha-mediated expression of MMP-9 protein and cell invasion through the suppression of JNK pathway and microRNA 221 in human pancreatic adenocarcinoma cancer cells. PLoS One. 2021;6(3): e0247550.

95 Kakwre H, Ingham ES, Tumbale SK, Ferrara KW. Gemicitabine-retinoic prodrug loaded nanoparticles display in vitro antitumor efficacy towards drug-resistant human PANC-1 pancreatic cancer cells. Mater Sci Eng C Mater Biol Appl. 2020 Dec;117: 111251.

96 Nakagawa T, Shimizu M, Shirakami Y, Tatebe H, Yasuda I, Tsurumi H, et al. Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells. Cancer Lett. 2009 Jan;273(2): 250–6.

97 Nakagawa T, Shimizu M, Shirakami Y, Tatebe H, Yasuda I, Tsurumi H, et al. Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells. Cancer Lett. 2009 Jan;273(2): 250–6.